Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on August 5, 2022, for SANUWAVE Health, Inc. The filing primarily details a private placement financing transaction, the settlement of prior indebtedness, and a change in board leadership.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company received total proceeds of $14.4 million in cash at closing.
- Debt Instrument: Issued future advance convertible promissory notes with an aggregate principal amount of approximately $16.1 million. This principal includes $12.2 million in new capital and $3.8 million in rolled-forward accrued expenses and fees.
- Interest Rate: Notes bear interest at 15% per annum.
- Conversion Terms: Notes are convertible at a price of $0.04 per share, subject to anti-dilution adjustments and a floor of $0.01.
- Warrants Issued:
- 403 million shares at an exercise price of $0.067 per share (First Warrants).
- 403 million shares at an exercise price of $0.04 per share (Second Warrants).
- Warrants have a five-year term.
- Debt Settlement: Satisfied prior indebtedness to Leviston Resources LLC via a payment of $3,205,715 and the issuance of 16,666,667 shares of common stock.
Material Changes and Agreements
The filing reports the entry into a Material Definitive Agreement (Securities Purchase Agreement) and the termination of a prior agreement with Leviston Resources LLC. The new financing is secured by a Security Agreement and includes a Subordination Agreement where the new notes are subordinate to obligations held by NH Expansion Credit Fund Holdings LP. Additionally, a Registration Rights Agreement was executed, requiring the Company to file a registration statement within 60 days and have it effective within 180 days.
Management Commentary, Governance, and Risks
- Board Appointment: Morgan Frank was appointed to the Board of Directors to serve as Chair, effective immediately, in connection with the financing.
- Conversion Triggers: Notes and Warrants become convertible/exercisable upon the earlier of a reverse stock split or December 31, 2022.
- Dilution Risk: The issuance of 806 million warrant shares and the conversion of $16.1 million in notes at $0.04 per share represents significant potential dilution to existing shareholders.
- Listing Contingency: Conversion and exercise prices are subject to adjustment if the Company lists on the Nasdaq Capital Market and the average volume weighted average price is less than $0.04 per share.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-closing to assess the dilution impact of the 806 million warrants and potential note conversions.
- Confirm the status of the reverse stock split mentioned as a trigger for conversion.
- Review the full text of the Subordination Agreement to understand the priority of claims relative to NH Expansion Credit Fund Holdings LP.
- Monitor the filing of the Registration Statement required within 60 days of August 5, 2022.
- Assess the Company's liquidity position given the 15% interest rate on the new debt and the cash outflow for the Leviston settlement.